Achilles Therapeutics plc American Depositary Shares - ACHL STOCK NEWS

Achilles Therapeutics (ACHL) announced key developments in its clinical trials and business operations as of May 10, 2022. They dosed the first patient in the CHIRON trial for advanced non-small cell lung cancer (NSCLC) with a higher-dose cNeT therapy and initiated enrollment for THETIS Cohort B, targeting metastatic melanoma. The company reported a robust cash balance of $236.9 million, sufficient to maintain operations into the second half of 2024. R&D expenses rose to $13 million, reflecting increased trial activities, while the net loss for Q1 2022 stood at $17.4 million.

Achilles Therapeutics (NASDAQ: ACHL) has announced significant progress in its clinical trials. The first patient received a personalized clonal neoantigen-reactive T cell (cNeT) in the CHIRON trial for advanced non-small cell lung cancer (NSCLC). Following a positive review by the Independent Data Safety Monitoring Committee, enrollment for THETIS Cohort B has also begun, testing cNeT with a PD-1 inhibitor for metastatic melanoma. Results from both trials are anticipated in the second half of 2022, highlighting the company's commitment to treating difficult cancers.

Achilles Therapeutics (NASDAQ: ACHL) announced the appointment of Bernhard Ehmer as a Non-Executive Director, enhancing the Board with his extensive experience in R&D and regulatory affairs. Previously, Ehmer held leadership roles in several biotech firms, including CEO of Biotest AG. The company also reported the resignation of Derek DiRocco from the Board on May 3, 2022. This transition comes as Achilles focuses on advancing its precision T cell therapies targeting cancer, supported by its proprietary PELEUS™ bioinformatics platform.

Achilles Therapeutics (NASDAQ: ACHL) announced its participation in two key conferences this May. The Bank of America 2022 Healthcare Conference will be held from May 9-13 in Las Vegas, where CEO Iraj Ali will speak on May 11 at 4:00 PM PT. Additionally, at the H.C. Wainwright Global Investment Conference from May 23-26 in Miami, VP Lee Stern will present on May 24 at 5:00 PM ET. Achilles focuses on developing precision T cell therapies for solid tumors, utilizing its proprietary PELEUS™ bioinformatics platform.

Achilles Therapeutics (NASDAQ: ACHL) announced a significant expansion in clinical manufacturing capabilities in the UK and US. The UK facility at the Cell & Gene Therapy Catapult has achieved GMP certification and will support ongoing Phase I/IIa trials with a new capacity for 600 doses of personalized cNeT therapies. The US partnership with the Center for Breakthrough Medicines will enhance supply chain operations with up to 200 doses. This expansion is expected to strengthen clinical operations and support future growth in treating advanced cancers.

Achilles Therapeutics (NASDAQ: ACHL) announced its participation in key conferences throughout April 2022 to discuss its innovative T cell therapies for solid tumors. On April 5, CEO Iraj Ali will join a panel at the Accelerating Bio-Innovation 2022 in Cambridge. Subsequently, he will present at the Needham Virtual Healthcare Conference on April 12, and attend the Kempen Life Sciences Conference on April 20 for investor meetings. A significant KOL webcast on April 14 will feature Professor Charles Swanton discussing the implications of the TRACERx study for personalized cancer treatment.

Achilles Therapeutics plc (NASDAQ: ACHL) announces a KOL webcast scheduled for April 14, 2022, at 10:30 AM ET. The event will feature Professor Charles Swanton, who will discuss the TRACERx study's role in identifying clonal neoantigens for personalized T cell therapies. The TRACERx study, with over 3,200 tumor samples from 800 lung cancer patients, is crucial for validating Achilles’ AI-powered PELEUS platform. The webcast will include presentations from key experts and a Q&A session moderated by Dr. Joseph Catanzaro.

Achilles Therapeutics (NASDAQ: ACHL) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference, scheduled for March 15-17, 2022. CEO Iraj Ali will present an overview of the company and its pipeline on March 15 at 8:00 am ET. A live and recorded webcast of the presentation will be accessible via the Achilles website. The company specializes in precision T cell therapies targeting clonal neoantigens, with ongoing Phase I/IIa trials for advanced non-small cell lung cancer and metastatic melanoma.

Achilles Therapeutics (ACHL) reported its Q4 and full-year 2021 financial results, highlighting significant data on its cNeT therapies aimed at treating solid tumors. The company holds $266 million in cash, sufficient to fund operations through mid-2024, including ongoing clinical trials. Notable developments include plans to dose patients with higher-dose cNeT therapies and initiate a tumor archiving program in 2022. They have made advancements in both R&D and manufacturing capabilities, and continue to expand their U.S. presence with a new headquarters in Philadelphia.